BRD4‐IRF1 axis regulates chemoradiotherapy‐induced PD‐L1 expression and immune evasion in non‐small cell lung cancer
Clinical and Translational Medicine2022Vol. 12(1), pp. e718–e718
Citations Over TimeTop 10% of 2022 papers
Jian Wang, Yingzhuo Xu, Xinrui Rao, Ruiguang Zhang, Jing Tang, Dan Zhang, Xiaohua Jie, Kuikui Zhu, Xu Wang, Yunhong Xu, Sheng Zhang, Xiaorong Dong, Tao� Zhang, Kunyu Yang, Shuangbing Xu, Rui Meng, Gang Wu
Abstract
The data showed that BRD4-targeted therapy synergized with chemoradiotherapy and anti-PD-1 antibody by boosting anti-tumour immunity in NSCLC.
Related Papers
- → Evasion Techniques Efficiency Over The IPS/IDS Technology(2019)20 cited
- → Network Intrusion Detection: Automated and Manual Methods Prone to Attack and Evasion(2006)35 cited
- → Molecular Epidemiology of Female Lung Cancer(2011)10 cited
- → The Problem of NIDS Evasion in Mobile Networks(2011)6 cited
- Pragmatic Analysis of Deliberately Evasion(2013)